By Suherman Candra Maholtra 
In a significant advancement for global public health, researchers at Johns Hopkins Medicine and the Johns Hopkins Bloomberg School of Public Health have announced the development of an experimental therapeutic DNA vaccine for tuberculosis (TB) that is administered intranasally. This novel vaccine is specifically engineered to bolster the immune system’s ability to identify and eradicate "persisters"—a specialized population of drug-tolerant TB bacteria that often survive standard, months-long antibiotic courses and serve as the primary catalyst for disease relapse. The study, published in the Journal of Clinical Investigation, provides a potential roadmap for shortening treatment regimens and combating the rising tide of multidrug-resistant tuberculosis.
The Global Crisis of Tuberculosis Persistence
Tuberculosis remains one of the most formidable challenges in the history of human medicine. Having afflicted the human species for at least 6,000 years, Mycobacterium tuberculosis continues to claim more lives annually than any other single infectious pathogen, with the exception of the peak years of the COVID-19 pandemic. According to 2024 data from the World Health Organization (WHO), the scale of the crisis is immense: approximately 2 billion people, or one-quarter of the world’s population, carry a latent TB infection. While these individuals do not show symptoms, they represent a massive reservoir for future active disease.
In 2024 alone, over 10 million people progressed to active TB, and 1.2 million succumbed to the illness. The primary hurdle in eradicating TB lies in the bacteria’s ability to enter a state of dormancy or "persistence" when under stress. These persister cells are metabolically inactive, making them largely impervious to traditional antibiotics that typically target actively dividing cells. Consequently, TB treatment requires a rigorous six-month regimen of multiple drugs—a schedule that is difficult for many patients to complete, leading to treatment failure, relapse, and the emergence of drug-resistant strains.
A Genetic Strategy: The Mechanism of the DNA Fusion Vaccine
The experimental vaccine developed at Johns Hopkins utilizes a sophisticated genetic approach to overcome the bacterial "cloaking" mechanism. Lead author Styliani Karanika, M.D., an assistant professor of medicine at the Johns Hopkins University School of Medicine and a faculty member of the Johns Hopkins Center for Tuberculosis Research, explained that the vaccine functions by fusing two specific genes: relMtb and Mip3α.
The first component, the relMtb gene, is a critical survival tool for the TB bacterium. Under hostile conditions—such as exposure to antibiotics, low oxygen levels, or nutrient scarcity—the bacterium uses this gene to produce the RelMtb protein. This protein triggers a "stringent response" that allows the microbe to enter a drug-tolerant state. By including this gene in the vaccine, the researchers are essentially training the immune system to recognize the very tool the bacteria use to hide.
The second component, the Mip3α gene, acts as a biological "homing beacon." When fused with relMtb, it produces a signal that attracts immature dendritic cells. These are the "sentinels" of the immune system; they ingest the TB proteins and "present" them to T cells. This presentation is the vital step required to coordinate a targeted, aggressive attack by the body’s immune system against the persistent bacteria.
The Strategic Advantage of Intranasal Delivery
A distinctive feature of this therapeutic vaccine is its delivery method. Unlike traditional vaccines administered via intramuscular injection, this DNA vaccine is delivered through the nose. This strategy is designed to trigger mucosal immunity directly at the site of infection.
"Intranasal delivery focuses vaccination on the respiratory mucosa in the lungs where TB infection occurs," Dr. Karanika noted. By concentrating the immune response in the airways and lung tissue, the vaccine generates localized T-cell immunity. This is complemented by a systemic immune response that circulates through the bloodstream, providing a dual layer of protection that is often absent in traditional vaccination methods.
The respiratory tract is the primary entry point and battleground for TB. By establishing a robust "local guard" of immune cells in the lungs, the vaccine aims to prevent the bacteria from establishing a foothold or retreating into a dormant state within lung lesions.
Experimental Results: Mice and Nonhuman Primates
The research team conducted a series of rigorous animal trials to test the efficacy and durability of the vaccine. In mouse models, the results were highly promising. When administered alongside first-line TB drug therapy, the intranasal DNA fusion vaccine significantly accelerated the clearance of the bacteria from the lungs. Furthermore, the vaccinated mice showed a marked reduction in lung inflammation and, most importantly, a complete prevention of disease relapse after the antibiotic treatment ended.
One of the most critical findings involved the vaccine’s synergy with modern drug combinations. The researchers tested the vaccine in conjunction with the "BPaL" regimen—a powerful combination of bedaquiline, pretomanid, and linezolid used to treat highly drug-resistant TB. The vaccine enhanced the effectiveness of these drugs, suggesting that immunotherapy could be a vital tool in managing the most difficult-to-treat cases of multidrug-resistant TB (MDR-TB).
Following the success in mice, the team transitioned to studies involving rhesus macaques to evaluate the vaccine’s translational potential. The macaques received the intranasal DNA vaccine and demonstrated measurable, TB-specific immune responses in both their bloodstream and their airways. These responses included the activation of CD4 "helper" T cells and CD8 "killer" T cells, both of which are essential for controlling intracellular pathogens like M. tuberculosis.
The immune responses in the primates were observed to last for at least six months. This longevity is a crucial metric, as it suggests the vaccine could provide the durable protection necessary to cover the duration of long antibiotic treatments and beyond. While the primate study focused on immune activation rather than direct challenge with live TB, the data provide a critical "translational bridge" toward human clinical trials.
Shifting the Paradigm: From Antibiotics to Immunotherapy
The Johns Hopkins study supports a growing consensus in the scientific community that relying solely on antibiotics may not be sufficient to end the global TB epidemic. The World Health Organization has long advocated for the development of therapeutic vaccines that can complement existing drug treatments.
The current paradigm focuses on killing actively replicating bacteria. However, this leaves the "persisters" untouched, requiring months of additional medication to ensure total eradication. By using immunotherapy to target the persistent state, clinicians could potentially:
- Shorten Treatment Duration: If the immune system can effectively clear persisters, the standard six-month treatment could be significantly reduced, improving patient compliance.
- Reduce Relapse Rates: Eliminating the reservoir of dormant bacteria would prevent the disease from "waking up" months or years after treatment.
- Combat Resistance: By making standard drugs more effective and providing an alternative pathway for bacterial clearance, the vaccine could slow the evolution of drug-resistant strains.
DNA vaccines offer several practical advantages in this context. They are generally more stable than traditional protein-based vaccines and do not require the stringent "cold chain" logistics that complicate vaccine distribution in developing nations. Furthermore, they can be produced rapidly and efficiently at scale.
Timeline and Future Directions
While the results are encouraging, the transition from animal models to human application requires further validation. The research team is currently planning additional preclinical work to refine the dosage and safety profiles.
"These nonhuman primate data are encouraging because they show that the Mip3α/relMtb vaccine can generate durable, antigen-stimulated immune responses in an animal model whose immune system more closely resembles that of humans," Dr. Karanika stated.
The timeline for human clinical trials will depend on regulatory approvals and the securing of further funding. However, the intellectual property framework is already in place, with Karanika and several colleagues listed as inventors on a pending patent for the Mip3α/relMtb vaccine technology.
Collaborative Effort and Funding
The study was a multi-disciplinary effort involving a large team of researchers from various departments at Johns Hopkins. Co-authors included Tianyin Wang, Addis Yilma, Jennie Ruelas Castillo, and James Gordy, among others. The project drew on expertise from the Johns Hopkins Center for Tuberculosis Research and the Center for HIV/AIDS, reflecting the frequent co-infection of these two pathogens in global health settings.
Funding for this groundbreaking research was provided by several grants from the National Institutes of Health (NIH), including the National Institute of Allergy and Infectious Diseases. Additional support was provided by the Gilead HIV Research Scholar Award, the Willowcraft Foundation, and the Potts Memorial Foundation, underlining the broad institutional support for innovative TB solutions.
As the global medical community continues to struggle with the persistence of tuberculosis, the Johns Hopkins intranasal DNA vaccine represents a hopeful shift toward a more integrated approach—one that combines the precision of genetic engineering with the natural power of the human immune system to finally turn the tide against an ancient killer.
